Gt biopharma announces interim gtb-3550 trike™ monotherapy clinical trial results at 2021 raymond james human health innovation conference

Beverly hills, calif., june 23, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary nk cell engager (trike™) protein biologic technology platform, announced jeffrey s.

GTBP Ratings Summary

GTBP Quant Ranking